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Abstract 
In vitro, nitric oxide (NO) has been shown to have antimicrobial activity against a wide range of 
viruses, including influenza A virus. Therefore, we hypothesized that inhaled nitric oxide 
(iNO) would increase survival in vivo by reducing the viral load in C57Bl/6 mice infected with 
a lethal dose of influenza A/WSN/33 (H1N1; WSN/33) virus. NO was delivered to influen-
za-infected mice either continuously or intermittently at 80 or 160 ppm, respectively, using 
both prophylactic and post-infection treatment strategies. Murine survival and weight loss 
were assessed, and lung viral load was quantified via plaque assay. Here, we report that iNO 
administered prophylactically or post-influenza infection failed to improve survival of infected 
mice. No difference in lung viral load was observed between experimental groups. Although 
NO has antiviral activity against influenza A virus in vitro, iNO therapy provided no apparent 
benefit when used for treatment of influenza A virus infection in vivo. 
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INTRODUCTION 
Influenza A viruses infect approximately 5–15% 
of  the  population,  resulting  in  250–500  thousands 
deaths each year (1). The most widely used class of 
drugs for treatment of clinical influenza is the neu-
raminidase  inhibitors,  including  oseltamivir  and 
zanamivir. The clinical impact of these drugs is lim-
ited by the development of antiviral drug resistance. 
Specifically, decreased efficacy of neuraminidase in-
hibitors  has  been  reported  against  seasonal  H1N1 
influenza  and  2009  novel  swine-origin  H1N1  influ-
enza, as well as avian influenza H5N1 virus (2-9). In 
addition, initiation of antiviral therapy in influenza A 
virus-infected  individuals  beyond  the  first  48–72 
hours after the onset of influenza symptoms is asso-
ciated with greater mortality and decreased antiviral 
efficacy  compared  with  treatment  initiated  within 
48–72 hours of symptom onset (10–15). These caveats 
underscore the need to develop novel and effective 
influenza therapeutic strategies. Further investigation 
of  other  intervention  strategies  which  have  shown 
promising results against influenza A viruses in vitro 
but have not been investigated in vivo are warranted.  
Nitric  oxide  (NO)  is  an  important  cellular  sig-
nalling molecule synthesized from L-arginine by NO 
synthase (NOS). There are three types of NOS: con-
stituent  and  calcium-dependant  isoforms  that  are 
principally present in endothelial and neuronal cells 
(eNOS and nNOS, respectively), and the inducible or 
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calcium-independent isoform, iNOS (16). In the air-
ways, NOS is present in a variety of cells, including 
macrophages, vascular endothelial cells, airway epi-
thelial cells and neurons where NOS activity is known 
to  mediate  neurotransmission,  smooth  muscle  con-
traction  and  mucin  secretions.  NO  is  also  a  well 
known  biological  mediator  in  the  host  response  to 
infection (16, 17). Various inflammatory stimuli such 
as LPS and cytokines  including IFNg and TNF can 
cause  high  and  sustained  NO  production  by  iNOS; 
depending on the species, strain, infection dose and 
pathogen entry route, iNOS activity can result in pro- 
or anti-inflammatory responses, cytotoxicity, or cyto-
protection [reviewed in (16)].  
In  vitro,  NO  antimicrobial  activity  has  been 
demonstrated against a variety of viruses including 
ectromilia virus, vaccinia virus, herpes simplex type 1 
viruses, coronavirus, and influenza A and B viruses 
(18–22).  In  these  studies,  administration  of  the  NO 
donor S-nitroso-N-acetylpenicillamine (SNAP) to vi-
rus-infected cells significantly reduced viral burden. 
A human trial for treatment of severe acute respira-
tory syndrome (SARS) found inhaled NO (iNO), at 30 
ppm  or  less,  decreased  the  spread  and  intensity  of 
lung infiltrates and improved arterial oxygen satura-
tion (23).  
Severe cases of influenza infection are often as-
sociated with multisystem organ failure and hypox-
emic  respiratory  failure,  including  acute  lung  inju-
ry/acute respiratory distress syndrome (ALI/ARDS) 
requiring  advanced  mechanical  ventilatory  support 
(24,  25).  Affected  individuals  may  receive  ‘rescue’ 
therapies, including iNO,  in an attempt to improve 
outcome  (25).  However,  iNO  administration  for 
ARDS  secondary  to  viral  pneumonia  has  not  been 
specifically reported to improve clinical outcome (24, 
25).  
The  objective  of  this  study  was  to  determine 
whether iNO administration could reduce viral load 
and  improve  survival  in  a  murine  model  of  severe 
influenza. Inhaled NO delivery would provide a safer 
and  easier  delivery  method  rather  than  administra-
tion of NO donors, as iNO is approved for treating 
term and near-term neonates with hypoxemic respir-
atory failure up to a dose of 80 parts per million (ppm) 
(26, 27). It has been reported that exogenous gaseous 
NO (gNO) at a high dose of no less than 160 ppm and 
with five hours of continuous exposure, can elicit a 
non-specific  antimicrobial  response  against  a  broad 
range of microorganisms in vitro (28). In vivo, 160 ppm 
iNO treatment would result in NO binding to hemo-
globin to form methemoglobin, resulting in reduced 
oxygen transport and hypoxemia, as well as the po-
tential for elevated levels of the harmful NO metabo-
lite NO2. However, Miller et al. (29) has shown that 
gNO in an intermittent delivery regimen of 160 ppm 
for 30 min every 3.5 hours can prevent methemoglo-
binemia and reduce the potential of host cell toxicity 
in vitro  and  in vivo (Miller  C,  personal  communica-
tion), while retaining antimicrobial properties in vitro. 
RESULTS 
Continuous iNO at 80 ppm decreased survival 
and intermittent high dose iNO at 160 ppm did 
not increase survival of influenza A vi-
rus-infected mice  
We evaluated the ability of iNO to improve sur-
vival of influenza A/WSN/33 (mouse-adapted H1N1 
strain; WSN/33) infected mice. Experimental C57Bl/6 
mice  were  inoculated  intranasally  with  an  80–100% 
lethal  dose  of  WSN/33  (1000  PFU).  At  5  days 
post-infection, the majority of mice in all experimental 
groups experienced weight loss (Fig. 1a and 2a). At 7 
days post-infection, mice began to reach euthanasia 
criteria  (≤80%  of  day  0  weight),  and  by  day  10 
post-infection,  most  mice  were  euthanized  (Fig.  1b 
and 2b). If 20% weight loss was not met by day 10 
post-infection,  the  infection  typically  resolved,  and 
surviving mice gained weight.  
Weight loss over the course of infection was ac-
celerated in mice administered continuous iNO at 80 
ppm starting 1 hour prior to inoculation compared to 
infected control mice receiving compressed room air 
(P < 0.001) (Fig. 1a). Continuous iNO administration 
at 80 ppm starting 1 hour prior to inoculation signifi-
cantly  decreased  survival  of  WSN/33-infected  mice 
compared  to  infected  control  mice  administered 
compressed room air (P < 0.01). During the course of 
infection, 100% of continuous iNO treated mice were 
euthanized compared to 80% of infected control mice 
(Fig. 1b). Intermittent iNO administration at 160 ppm 
for 30 min intervals every 3.5 hours starting either 1 
hour  prior  to  or  4  hours  post-infection  resulted  in 
similar weight loss kinetics (Fig. 2a) and consequent 
survival kinetics (Fig. 2b) of infected mice compared 
to  infected  control  mice  administered  compressed 
room air.  
Continuous or intermittent iNO administra-
tion does not reduce lung viral load 
As gaseous NO (gNO) at high concentrations has 
been shown to decrease the viral load of infected cells 
in vitro  (Miller  C,  personal  communication),  we  ex-
amined whether iNO could reduce the viral load of 
influenza virus-infected mice. iNO was administered 
starting 1 hour prior to influenza WSN/33 infection 
and continued either continuously at 80 ppm or in-Int. J. Med. Sci. 2012, 9 
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termittently at 160 ppm for 30 min every 3.5 hours 
until mouse lungs were harvested at peak influenza 
viral  load  in  the  lungs  (determined  to  be  day  5 
post-infection based on preliminary studies, data not 
shown).  Since  iNO  was  administered  both  prior  to 
and  for  5  days  post-infection,  we  were  able  to  test 
whether iNO at intermediate (80 ppm) or high con-
centration (160 ppm) could prevent either viral entry 
or viral replication in vivo, and thereby reduce viral 
load. Continuous iNO at 80 ppm, intermittent iNO at 
160  ppm,  and  compressed  room  air  administration 
yielded similar lung viral loads of infected mice on 
day  5  post-infection  (Fig.  3a  and  b,  respectively). 
Therefore,  both  continuous  and  intermittent  iNO 
administration failed to reduce lung viral load of in-
fected  mice,  compared  to  infected  control  mice  ad-
ministered compressed room air.  
 
 
 
Figure 1. Prophylactic iNO therapy increased weight loss and decreased survival of C57Bl/6 mice infected with influenza 
A/WSN/33. C57Bl/6 male mice were infected with 10
3 PFU WSN/33 and administered continuous NO at 80 ppm (grey) or 
compressed room air (black) starting 1 hour prior to infection (n=17–18/group, two independent pooled experiments). (a) 
Mice receiving iNO displayed a significant reduction in weight compared to infected controls (Two-way ANOVA p < 0.001 
with Bonferroni post-tests: P < 0.01 on day 6 and 7 post-infection). Error bars represent standard deviations. (b) iNO 
significantly reduced survival of treated mice compared to infected controls as shown by Kaplan-Meir survival curves 
(log-rank test: P < 0.01).  
 
 
 
Figure 2. Prophylactic and post-infection intermittent iNO did not alter (a) weight loss kinetics or (b) survival of C57Bl/6 
mice infected with 10
3 PFU WSN/33. C57Bl/6 male mice were infected with 10
3 PFU of WSN/33 and administered in-
termittent NO at 160 ppm for 30 min intervals every 3.5 hours starting either 1 hour prior to infection (light grey) or 4 
hours post-infection (dark grey). Infected controls were administered compressed room air (black) (n=9–10/group). Error 
bars represent standard deviations. Int. J. Med. Sci. 2012, 9 
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Figure 3. Intermittent high dose iNO prophylactic therapy failed to decrease viral load of C57Bl/6 mice infected with 
influenza WSN/33. Lungs were collected 5 days post-WSN/33 infection from mice treated with (a) continuous NO at 80 
ppm (grey) or compressed room air (black) starting 1 hour prior to infection (n=5/group) or (b) intermittent NO at 160 
ppm (grey) or compressed room air (black) for 30 min  intervals every 3.5 hours starting 1 hour prior to infection 
(n=5/group). Error bars represent standard deviations. Lung viral load was quantified for all experimental groups by plaque 
assay on MDCK cells. 
 
DISCUSSION 
iNO therapy is currently FDA approved for the 
treatment  of  term  and  near-term  neonates  with  hy-
poxemic respiratory failure associated with clinical or 
echocardiographic  evidence  of  pulmonary  arterial 
hypertension  (26,27).  Variable  findings  have  been 
reported  for  iNO  efficacy  when  administered  at  1 
ppm and up to 80 ppm. For its indicated use, iNO has 
been  found  to  increase  vasodilation,  improve  oxy-
genation,  reduce  length  of  mechanical  ventilation, 
reduce  oxygen  requirement,  and  decrease  length  of 
stay in the intensive care unit (27, 30, 31). However, 
systematic  reviews  have  failed  to  demonstrate  that 
iNO therapy reduces overall mortality (32, 33).  
Systematic  reviews  and  meta-analysis  of  ran-
domized controlled trials have shown that iNO, when 
used  therapeutically  in  the  management  of  ARDS, 
results in a transient improvement in arterial oxygen-
ation but does not reduce mortality (34–36). Moreo-
ver, iNO therapy for ARDS may increase the risk of 
iNO  treated  patients  developing  renal  dysfunction 
(35, 36). Despite this, 39% of critical care specialists 
surveyed reported using iNO for the management of 
patients with ARDS in Ontario, Canada (37).  
Typically, iNO is administered at initial doses of 
5–20 ppm in randomized controlled trials and obser-
vational  studies  for  neonatal  hypoxic  respiratory 
failure  (27).  Although  FDA-approved  at  concentra-
tions up to 80 ppm, no specific dose of iNO has been 
proven  more  advantageous  than  another  (27,  34). 
Rather,  methemoglobinemia,  defined  as  7%  methe-
moglobin in Davidson et al. (38), was more likely to 
occur. Methemoglobinemia may account for the de-
crease in survival observed in our study with contin-
uous iNO administration at 80 ppm. NO2 concentra-
tions were measured daily over the course of infection 
and kept below 2 ppm as is acceptable in humans, 
however, lung toxicity may still explain these results 
as the toxic threshold in mice may be lower. On the 
other  hand,  given  previous  in  vitro  findings  by 
McMullen et al. (28), 80 ppm may also have been too 
low of a concentration to provide an antiviral effect.  
A high dose of NO at 160 ppm was administered 
intermittently, not to target the airway vessels specif-
ically,  but  rather  to  induce  an  antimicrobial  effect 
while avoiding the harmful effects of high dose con-
tinuous iNO delivery. iNO administered to influenza 
infected mice in this manner, either prophylactically 
or  therapeutically,  failed  to  improve  survival  of  in-
fected mice, change the course of weight loss, or de-
crease the lung viral load, compared to control mice 
receiving  compressed  air.  Therefore,  although  ad-
ministration of high dose intermittent iNO may have 
reduced the harmful side-effects of NO, antimicrobial 
activity was not observed in vivo.  
In conclusion, despite the demonstrated antimi-
crobial  activity  of  NO  against  influenza  A  virus  in Int. J. Med. Sci. 2012, 9 
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vitro, the results of this study do not support the use of 
iNO as a prophylactic or treatment strategy to reduce 
viral  burden  or  improve  clinical  outcome  in  severe 
influenza in vivo. Furthermore, it may be difficult to 
achieve viricidal concentrations of NO in the airways 
using iNO at concentrations that are safe in the living 
host.  
MATERIALS AND METHODS 
Murine influenza model  
Animal  use  protocols  were  reviewed  and  ap-
proved  by  the  University  Health  Network  Ontario 
Cancer Institute Animal Care Committee, and all ex-
periments were conducted in accordance with insti-
tutional guidelines in an animal biosafety level 2 fa-
cility.  Female  C57Bl/6  mice,  9–11  weeks  old,  were 
obtained from Jackson Laboratories (Bar Harbor, ME, 
USA) and maintained under pathogen-free conditions 
with a 12-hour light cycle. On day 0, while under light 
isofluorane  anesthesia,  experimental  mice  were  in-
fected via nasal instillation with 103 plaque forming 
units  (PFU)  of  influenza  A/WSN/33  (H1N1; 
WSN/33,) (stock kindly provided by Dr. Eleanor Fish, 
University Health Network/University of Toronto) in 
50 μl PBS. Weight was recorded daily for a maximum 
of  twelve  days  post-infection,  and  mice  were  sacri-
ficed when euthanasia criteria was met (greater than 
20%  weight  loss).  Lung  tissue  was  harvested  for 
analysis on day 5 post-infection.  
In Vivo NO Delivery 
Prophylactic or post-infection iNO therapy was 
initiated  either  1  hour  prior  to  or  4  hours 
post-infection,  respectively.  Mice  were  placed  in 
flow-through chambers with free access to food and 
water and received either compressed room air, con-
tinuous  NO  at  80ppm  +/-5ppm  mixed  with  com-
pressed room air, or intermittent NO for 30 min every 
3.5 hours at 160ppm+/-5ppm mixed with compressed 
room  air.  Soda  lime  (200  g)  was  supplied  to  each 
chamber,  and  gas  flow  was  maintained  at  10–12 
L/min to scavenge and minimize NO2 levels, respec-
tively. NO2 levels were limited to <2 ppm for contin-
uous iNO therapy and <8 ppm for intermittent iNO 
therapy. NO and NO2 levels were measured using an 
AeroNOX machine (Pulmonox Medical, AB, CA).  
Lung influenza viral load analysis 
Lungs  were  harvested  and  frozen  at  -80°C. 
Lungs were thawed, weighed, and homogenized in 1 
ml PBS for 30 sec using a Tissue Miser homogenizer 
(Fisher Scientific, ON, CA). Lung homogenates were 
spun at 10,000xg for 10 min, aliquoted, and stored at 
-80°C for viral yield titration. Influenza WSN/33 viral 
yield in lung homogenates was quantified by plaque 
assay in MDCK canine kidney epithelial cells (ATCC, 
VA,  USA).  Cells  were  maintained  in  Eagle’s  MEM 
(ATCC, VA, USA) supplemented with 10% fetal bo-
vine serum and antibiotics. MDCK cells were cultured 
at 37°C with 5% CO2. Cells were plated at a concen-
tration  of  8x106  cells/plate  in  6  well  culture  plates. 
12–24 hours later, medium was removed and MDCK 
cells were washed twice with PBS. 10-fold dilutions of 
lung homogenates were added to MDCK cells in 500 
μL Eagle’s MEM, in duplicate, and incubated at 37°C 
with 5% CO2 for 1 hour with plates rocked every 15 
min. After incubation, 1 mL of serum-free 2X Eagle’s 
MEM supplemented with 8 μl/ml trypsin, 60 μl/ml of 
7.5%  sodium  bicarbonate  and  20  μl/ml  antibiotics, 
combined with 1 ml of 1.2% agarose, was added to 
each well. Once the agarose set, plates were incubated 
at 37°C for 42–72 hours until syncitia were observed. 
Plates were fixed with Carnoy’s fixative (3:1, metha-
nol:glacial acetic acid) for 30 min then stained with 
0.1% crystal violet in 20% ethanol to visualize plaques. 
Viral load is expressed as plaque forming units per 
gram of lung tissue (PFU/g). 
Statistical Analysis  
Log-rank tests were performed on Kaplan-Meier 
survival curves. Significant differences in weight loss 
between groups were assessed by two-way analysis of 
variance  (ANOVA)  and  Bonferroni  post-tests  were 
performed. A Student’s t-test was carried out on viral 
yield data to assess significant differences (p ≤ 0.05) 
between experimental groups. 
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